| Document |
Document Title |
|
WO/2005/054204A2 |
The invention relates to a class of polycyclic compounds that reacts with and neutralizes a reactive oxygen species, such as a free oxygen radical, in a patient and which can then be regenerated back to their original reactive chemical f...
|
|
WO/2005/051932A1 |
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...
|
|
WO/2005/051385A1 |
The present invention relates to substituted heterocyclic compounds, such as isoxazoloanthrones, and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compound...
|
|
WO/2005/051931A2 |
The present invention relates to isoxazoline derivatives of structure (I) and their analogues, which can be used as phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of AIDS, ...
|
|
WO/2005/048953A2 |
The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of amide compounds are employed. The invention also provides methods of using the compounds and/or compositions in th...
|
|
WO/2005/048948A2 |
The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of urea compounds are employed. The invention also provides methods of using the compounds and/or compositions in the...
|
|
WO/2005/049623A1 |
The present invention relates to compounds from the group of 1-aza-2-oxadibenzo[e,h]azulenes, their pharmacologically acceptable salts and solvates, processes and intermediates for the preparation thereof and to the use thereof for the...
|
|
WO/2005/049064A1 |
Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
|
|
WO/2005/049589A2 |
Disclosed are novel compounds of formula (I), having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acce...
|
|
WO/2005/047236A1 |
The present invention relates to sulfoxide and bis-sulfoxide compounds of formula (I), formula (II), or formula (III), compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiova...
|
|
WO2005012220A9 |
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. Formula (I) inc...
|
|
WO/2005/044808A1 |
The present invention describes an improved process for the preparation of 1,2Benzisoxazole-3-methanesulphonamide (Zonisamide), a well known anti-epileptic agent which possesses anti-convulsant and anti-neurotoxic effects. Other aspect o...
|
|
WO/2005/041959A1 |
The invention features phenoxyacetic acids and analogs of formula (I), compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2005/042513A1 |
There is provided a compound having Formula (I) R1-Z-R2 Formula (I) wherein R1 is an optionally substituted phenyl ring; R2 is or comprises an optionally substituted aromatic ring; and Z is -X-Y-L- or -Y-X-L- wherein either X is selected...
|
|
WO/2005/040121A2 |
The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
|
|
WO/2005/040161A1 |
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to biaryl containing compounds and methods for their preparation. These compounds may be...
|
|
WO/2005/040100A1 |
This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have ...
|
|
WO/2005/040138A1 |
This invention is related to compounds of general formula (I) wherein X is oxygen or sulphur or a NR7 group; R1 is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one o...
|
|
WO/2005/037271A2 |
The present invention provides a large conductance calcium-activated K channel opener comprising a compound of the formula (I): wherein R1 and R3 are each sulfonamide, carbamoyl, acyl, amino, and the like, m and n are each 0 to 2, R2 and...
|
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
|
WO/2005/035514A2 |
The present invention provides compounds of Formula (I) useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and su...
|
|
WO/2005/035510A1 |
The invention relates to novel derivatives of 4-phenylthiazoles and 4-phenylimidazoles and the use thereof as medicaments. The invention especially relates to the following compounds: butyl-2-[4-(4-aminophenyl)-1H-imidazol-2-yl]ethylcarb...
|
|
WO/2005/034848A2 |
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The pres...
|
|
WO/2005/033056A2 |
The present invention relates to novel compounds of Formula (I) with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation...
|
|
WO/2005/030738A1 |
The invention relates to an improved process for the preparation of 1,2-benzisoxazole-3-methane sulfonates and a novel compound 4-oximino-2,3-dihydrobenzoxathiin-2, 2-dioxides. The 1,2-benzisoxazole-2-methane sulfonates and 4-oximino...
|
|
WO/2005/026133A1 |
Isoxazole compounds of formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other disease in which peptide deformylases are involve...
|
|
WO/2005/023247A1 |
Disclosed are compounds and pharmaceutically acceptable salts thereof, useful as LXR agonists.
|
|
WO/2005/023759A2 |
Disclosed are compounds of the Formula (I) and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are defined in the specification. Such compounds are MEK inhibitors and useful in the trea...
|
|
WO/2005/021516A1 |
The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same
|
|
WO/2005/021536A2 |
The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.
|
|
WO/2005/020899A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/019174A1 |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
WO/2005/019151A1 |
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...
|
|
WO/2005/019147A2 |
There are described compounds of formula (I) wherein X1 and X2 are each independently of the other fluorine, chlorine or bromine; A1 and A2 are, for example, a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; R1 and R2 are, ...
|
|
WO/2005/019212A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019184A1 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/017037A1 |
The invention relates to the use of sulphonamide salts as catalysts for the oligomerisation of isocyanates and a method for NCO oligomerisation using said catalysts.
|
|
WO/2005/013914A2 |
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...
|
|
WO/2005/012280A1 |
The present invention is related to alkynyl aryl carboxamides of Formula (I’) and use thereof for the treatment and/or prevention of an inflammatory disorder, obesity and/or metabolic disorders mediated by insulin resistance or hypergl...
|
|
WO2003099793A9 |
A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, ...
|
|
WO/2005/012268A1 |
A compound represented by the general formula (I-A): (Chemical formula 1) (I-A) (wherein R1 is hydroxy, etc.; R2 is optionally substituted lower alkyl, etc.; R3 is hydrogen, etc.; R4 is optionally substituted allylene, etc.; R5 is a grou...
|
|
WO/2005/007620A2 |
The invention relates to new N-hydroxy-4-(3-phenyl-5-methyl-isoxazole-4-yl)-benzenesulfon
amide solvates of formula (I), wherein n represents 0 or 1 mol, [solvate] represents water, C1-C4 alcohol, Cl-C4 alkylester of C1-C3 carboxylic aci...
|
|
WO/2005/007621A2 |
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...
|
|
WO/2005/007635A2 |
The invention described herein relates to new combretastatin derivatives obtained by total synthesis and having the following general formula (I) in which the groups are as defined in the description here below. Said compounds, though ch...
|
|
WO/2005/004810A2 |
N-aryl arylsulfonamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
|
|
WO/2005/005389A2 |
The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.
|
|
WO/2004/113273A1 |
Compounds of formula (I), wherein A0, A1, and A2 are each independently of the others a bond or a Cl-C6alkylene bridge; A3 is a Cl-C6alkylene bridge which is unsubstituted or substituted by from one to six identical or different substitu...
|
|
WO/2004/113304A1 |
Compounds having the formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
|
|
WO/2004/111019A2 |
The invention relates to the use of compounds of general formula (I) in the form of cleavable protective groups, in particular bioactive or chromogen, cleavable by serumal albumin.
|
